Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86


Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer.

Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG.

Ann Surg Oncol. 2018 Mar 1. doi: 10.1245/s10434-018-6363-3. [Epub ahead of print]


Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K.

Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29.


Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.


MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer.

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K.

Oncotarget. 2017 Jun 27;8(37):61800-61809. doi: 10.18632/oncotarget.18694. eCollection 2017 Sep 22.


Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.


Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial.

Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B.

Ann Surg. 2018 Feb;267(2):199-207. doi: 10.1097/SLA.0000000000002353.


Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476. doi: 10.1111/pcmr.12599. Epub 2017 Jul 4.


Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR.

Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17.


Pathway-based classification of breast cancer subtypes.

Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1697-1712.


Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21.


Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K.

Clin Exp Metastasis. 2017 Jan;34(1):51-62. doi: 10.1007/s10585-016-9829-3. Epub 2016 Nov 3.


Expression and clinical significance of Wee1 in colorectal cancer.

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K.

Tumour Biol. 2016 Sep;37(9):12133-12140. Epub 2016 May 24.


Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer.

Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K.

Ann Surg Oncol. 2017 Mar;24(3):721-728. doi: 10.1245/s10434-016-5621-5. Epub 2016 Oct 20.


Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H.

Br J Cancer. 2016 Oct 11;115(8):929-939. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6.


microRNAs as cancer biomarkers.

Flatmark K, Høye E, Fromm B.

Scand J Clin Lab Invest Suppl. 2016;245:S80-3. doi: 10.1080/00365513.2016.1210330. Epub 2016 Aug 9.


Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH.

Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28.


Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH.

BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x.


Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K.

Cancer Med. 2016 Aug;5(8):1840-9. doi: 10.1002/cam4.766. Epub 2016 Jun 8.


Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K.

J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290. Epub 2016 May 12.


Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH.

Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995.


Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH.

Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8.


Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report.

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K.

World J Surg Oncol. 2016 Mar 3;14:63. doi: 10.1186/s12957-016-0818-4.


Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14.


High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.


A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.

Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ.

Annu Rev Genet. 2015;49:213-42. doi: 10.1146/annurev-genet-120213-092023. Epub 2015 Oct 14. Review.


Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM.

Clin Exp Metastasis. 2015 Dec;32(8):755-67. doi: 10.1007/s10585-015-9742-1. Epub 2015 Sep 9.


Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.

Hektoen HH, Ree AH, Redalen KR, Flatmark K.

J Enzyme Inhib Med Chem. 2016 Oct;31(5):779-86. doi: 10.3109/14756366.2015.1069286. Epub 2015 Aug 5.


Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6.


Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial.

Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K.

Colorectal Dis. 2015 Oct;17(10):O191-7. doi: 10.1111/codi.13065.


MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22.


Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial.

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B.

Trials. 2015 Mar 4;16:73. doi: 10.1186/s13063-015-0577-5.


Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR.

Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12.


Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E.

Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review.


High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K.

Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11.


Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.


B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø.

BMC Cancer. 2014 Aug 20;14:602. doi: 10.1186/1471-2407-14-602.


Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014.


The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y.

J Ovarian Res. 2014 Feb 15;7:23. doi: 10.1186/1757-2215-7-23.


Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.

Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K.

J Surg Oncol. 2014 May;109(6):521-6. doi: 10.1002/jso.23527. Epub 2013 Dec 17.


Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.


Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer.

Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J.

Clin Colorectal Cancer. 2013 Dec;12(4):261-6. doi: 10.1016/j.clcc.2013.06.003. Epub 2013 Sep 5.


Clinical significance of disseminated tumour cells in non-small cell lung cancer.

Rud AK, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K.

Br J Cancer. 2013 Sep 3;109(5):1264-70. doi: 10.1038/bjc.2013.450. Epub 2013 Aug 13.


Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer.

Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K.

PLoS One. 2013 Jun 18;8(6):e66165. doi: 10.1371/journal.pone.0066165. Print 2013.


Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y.

Int J Cancer. 2013 Sep 15;133(6):1497-506. doi: 10.1002/ijc.28158. Epub 2013 Apr 17.


Molecular modelling and simulations in cancer research.

Friedman R, Boye K, Flatmark K.

Biochim Biophys Acta. 2013 Aug;1836(1):1-14. doi: 10.1016/j.bbcan.2013.02.001. Epub 2013 Feb 14. Review.


Nuclear legumain activity in colorectal cancer.

Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM.

PLoS One. 2013;8(1):e52980. doi: 10.1371/journal.pone.0052980. Epub 2013 Jan 10. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/05c95441-890f-4707-a1bc-c4d386561191.


Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.

Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2012;7(11):e50806. doi: 10.1371/journal.pone.0050806. Epub 2012 Nov 30.


Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer.

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K.

BMC Cancer. 2012 Nov 2;12:505. doi: 10.1186/1471-2407-12-505.


Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K.

Radiat Oncol. 2012 Sep 27;7:165. doi: 10.1186/1748-717X-7-165.


EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer.

Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K.

Br J Cancer. 2012 Aug 7;107(4):667-74. doi: 10.1038/bjc.2012.293. Epub 2012 Jul 10.

Supplemental Content

Loading ...
Support Center